Skip to main content

Table 4 Comparison of primary and secondary outcomes within 48 h postoperatively

From: Use of sugammadex is associated with reduced incidence and severity of postoperative nausea and vomiting in adult patients with obesity undergoing laparoscopic bariatric surgery: a post-hoc analysis

Outcomes

Unmatched

 

After PSM

 

After IPTW

Sugammadex

(n = 92)

Neostigmine

(n = 113)

OR/MDa

(95% CI)

P value

 

Sugammadex

(n = 38)

Neostigmine

(n = 38)

OR/MDa

(95% CI)

P value

 

OR/MDa

(95% CI)

P value

PONV

13 (14.1)

76 (67.3)

0.08

(0.04–0.16)

< 0.001b

 

5 (13.2)

26 (68.4)

0.07

(0.02–0.22)

< 0.001b

 

0.54

(0.48–0.61)

< 0.001b

PON

5 (5.4)

15 (13.3)

0.38

(0.13–1.08)

0.060

 

4 (10.5)

7 (18.4)

0.52

(0.14–1.90)

0.328

 

0.77

(0.67–0.88)

< 0.001b

POV

8 (8.7)

61 (54.0)

0.08

(0.04–0.18)

< 0.001b

 

1 (2.6)

19 (50.0)

0.03

(0.01–0.22)

< 0.001b

 

0.60

(0.53–0.68)

< 0.001b

Rescue antiemetic therapy

4 (4.3)

38 (33.6)

0.09

(0.03–0.26)

< 0.001b

 

1 (2.6)

16 (42.1)

0.04

(0.01–0.30)

< 0.001b

 

0.70

(0.62–0.80)

< 0.001b

Water intake

1882.4 ± 485.5

1436.5 ± 526.4

445.8

(305.1–586.6)

< 0.001b

 

1932.9 ± 407.2

1510.5 ± 474.2

422.4

(220.3–624.4)

0.001b

 

419.5

(214.2–613.6)

< 0.001b

  1. Data are presented as mean ± standard deviation (SD), median (IQR) or n (%) as appropriate
  2. Abbreviations: CI confidence interval, MD mean difference, N/A not applicable, OR odds ratio, PONV postoperative nausea and vomiting, PON postoperative nausea, POV postoperative vomiting
  3. a Effect size: OR for PONV, PON, POV and rescue antiemetic therapy, and MD for water intake
  4. b Statistically significant (P < 0.05)